Eric S. Surrey

PURPOSE OF REVIEW: Endometriosis is a gynecologic disorder that can lead to debilitating chronic pelvic pain and infertility. Gonadotropin-releasing hormone agonists (GnRHa) have emerged as a primary medical therapy for patients with sympto…

OBJECTIVE: To determine whether endometrial expression of the integrin alpha(v)beta(3) vitronectin can predict which endometriosis patient subgroup will benefit from pre-IVF cycle prolonged GnRH agonist (GnRHa) therapy. DESIGN: Prospective…

This chapter reviews the evidence surrounding the effect of reproductive surgery for tubal abnormalities, endometriosis, and uterine fibroids on in vitro fertilization (IVF) cycle outcome. Salpingectomy and proximal tubal occlusion are two …

Pelvic endometriosis is associated with significant morbidity and decreased quality of life. The diagnosis of this condition is challenging: Symptoms vary considerably often mimicking those of other medical conditions. Laparoscopic visualiz…

PURPOSE: Evaluate the incidence of aberrant endometrial integrin (alphavbeta(3) vitronectin) expression in patients at high risk for implantation defects. MATERIALS AND METHODS: Retrospective case-control trial of 74 consecutive infertile …

Progestins, synthetic progestational agents, have been used in the management of symptomatic endometriosis both as primary therapy and as an adjunct to surgical resection. A variety of oral agents have been employed in this regard with inve…

The mechanisms by which endometriosis may compromise fertility and the roles of surgical and medical therapy are discussed in detail in earlier chapters. Appropriate surgical technique should overcome the mechanical distortion induced by en…

PURPOSE: To assess the effect on cycle outcome of surgery for endometriosis performed in the 6 months prior to in vitro fertilization-embryo transfer (IVF-ET). METHODS: Retrospective analysis of all patients with a primary diagnosis of end…

Management of infertility associated with endometriosis remains challenging. The clinician must rule out all other causes of infertility before creating a treatment plan. It is important to remember that women with infertility and endometri…

Purpose: To assess the effect on cycle outcome of surgery for endometriosis performed in the 6 months prior to in vitro fertilization–embryo transfer (IVF-ET). Methods: Retrospective analysis of all patients with a primary diagnosis of endo…

OBJECTIVE: To evaluate the effect of a 3-month course of GnRH agonist administered immediately before IVF-ET in infertile patients with endometriosis. DESIGN: Prospective, randomized trial. SETTING: Three tertiary care assisted reproducti…

In Brief OBJECTIVE To assess post-treatment effects in endometriosis patients of a 12-month course of GnRH agonist alone or with one of three “add-back” regimens. METHODS This is a post-treatment follow-up analysis of a randomized, double-m…

OBJECTIVE: To assess post-treatment effects in endometriosis patients of a 12-month course of GnRH agonist alone or with one of three "add-back" regimens. METHODS: This is a post-treatment follow-up analysis of a randomized, double-masked,…

Colorado Center for Reproductive Medicine, Englewood, Colorado Correspondence: Eric S. Surrey, MD, Colorado Center for Reproductive Medicine, 799 East Hampden Avenue, Suite #300, Englewood, CO 80110.

OBJECTIVE: To reach a consensus on the role of add-back therapy for patients with endometriosis administered GnRH agonists (GnRH-a). DESIGN: Results of consensus conference reviewing MEDLINE search of English language abstracts of both pro…

GnRH analogues have been demonstrated to be effective medical therapy for symptomatic endometriosis. The use of these agents has been limited to 6 months due to hypoestrogenic side effects. A variety of steroidal and nonsteroidal add-back r…

OBJECTIVE: To determine the duration of time to the recurrence of pain attributable to endometriosis after the discontinuation of treatment with danazol or a GnRH agonist (GnRH-a) in patients who have had a satisfactory response to the trea…